Vor Biopharma raises $42m to advance development of cell therapy product candidate for AML

This article was originally published here

Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Novartis Institutes for BioMedical Research (NIBR), and Osage University Partners also participated in the round along with Vor Co-founder PureTech

The post Vor Biopharma raises $42m to advance development of cell therapy product candidate for AML appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply